<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:24968107-6e3a-4f27-b8a9-f059f6f4e70d"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="90d4fecc-62c6-4eae-bb9d-0b228230eba1"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-04T11:49:38Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:85df221e-4871-4560-bc89-ea0ae6d9316e"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
							<status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="TitleA"><span lang="EN-GB" style="color:black">SUMMARY OF PRODUCT CHARACTERISTICS</span></p><p align="center" class="EMEABodyText" style="text-align:center"><span lang="EN-GB" style="color:black"> </span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">1.       NAME OF THE MEDICINAL PRODUCT</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 5 mg tablets</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 10 mg tablets</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 15 mg tablets</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 30 mg tablets</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 5 mg tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Each tablet contains 5 mg of aripiprazole.</span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">3.       PHARMACEUTICAL FORM</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Tablet</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 5 mg tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Rectangular and blue, engraved with "A-007" and "5" on one side.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 10 mg tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Rectangular and pink, engraved with "A-008" and "10" on one side.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 15 mg tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Round and yellow, engraved with "A-009" and "15" on one side.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 30 mg tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Round and pink, engraved with "A-011" and "30" on one side.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.       CLINICAL PARTICULARS</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.1     Therapeutic indications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.2     Posology and method of administration</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Posology</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia:</span></i><span lang="EN-GB" style="color:black;layout-grid-mode:line"> the recommended starting dose for ABILIFY is 10 mg/day or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black;layout-grid-mode: line">Manic episodes in Bipolar I Disorder:</span></i><span lang="EN-GB" style="color:black"> the recommended starting dose for <span style="layout-grid-mode: line">ABILIFY </span>is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. <span style="layout-grid-mode: line">The maximum daily dose should not exceed 30 mg.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black;layout-grid-mode: line">Recurrence prevention of manic episodes in Bipolar I Disorder</span></i><i><span lang="EN-GB" style="color:black">:</span></i><span lang="EN-GB" style="color:black"> for </span><span lang="EN-GB" style="color:black">preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. </span><span lang="EN-GB" style="color:black">Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents aged 15 years and older</span></i><span lang="EN-GB" style="color:black">: the recommended dose for <span style="layout-grid-mode: line">ABILIFY</span> is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using <span style="layout-grid-mode:line">ABILIFY</span> oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1). ABILIFY is effective in a dose range of 10 <span style="layout-grid-mode:line">mg/day</span> to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</span></i><span lang="EN-GB" style="color:black">: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ABILIFY oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1). Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, ABILIFY is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Irritability associated with autistic disorder:</span></i><span lang="EN-GB" style="color: black"> the safety and efficacy of ABILIFY in children and adolescents aged below 18 years have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Tics associated with Tourette’s disorder:</span></i><span lang="EN-GB" style="color:black"> the safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Special population</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Renal impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required in patients with renal impairment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The safety and efficacy of ABILIFY in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for female patients as compared to male patients (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Smoking status</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dose adjustments due to interactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Method of administration</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">ABILIFY</span><span lang="EN-GB" style="color:black"> is for oral use.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Orodispersible tablets or oral solution may be used as an alternative to ABILIFY tablets for patients who have difficulty swallowing ABILIFY tablets (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.3     Contraindications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.4     Special warnings and precautions for use</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Suicidality</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic <em><span style="font-style:normal">treatment</span></em>, including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients should accompany antipsychotic treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Cardiovascular disorders</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">QT prolongation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Other extrapyramidal symptoms</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In paediatric clinical trials of aripiprazole akathisia and Parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Neuroleptic Malignant Syndrome (NMS)</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Seizure</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elderly patients with dementia-related psychosis</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Increased mortality</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56 to 99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Cerebrovascular adverse reactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78 to 88 years). Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hyperglycaemia and diabetes mellitus</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. Patients treated with any antipsychotics, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hypersensitivity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Weight gain</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Dysphagia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></u></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Lactose</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Patients with attention deficit hyperactivity disorder (ADHD) comorbidity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Falls</span></u></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="background:white"><a name="_Hlk952060"><span style="color:black">Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2).</span></a></p><p class="MsoNormal" style="margin-left:.1pt;text-autospace:none"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.5     Interaction with other medicinal products and other forms of interaction</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">D<span style="layout-grid-mode:line">ue to its α</span><span class="BMSSubscript">1</span>-adrenergic receptor antagonism,<span style="layout-grid-mode:line"> aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for other medicinal products to affect <em><span style="font-style:normal">aripiprazole</span></em></span></u></p><p class="EMEABodyText"><em><u><span lang="EN-GB" style="color:black;font-style: normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A gastric acid blocker, the H<sub>2</sub> antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. <span style="layout-grid-mode:line">Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Quinidine and other CYP2D6 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> was unchanged. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %</span></span><span lang="EN-GB" style="color:black">, respectively</span><span lang="EN-GB" style="color:black;layout-grid-mode:line">. Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Ketoconazole and other CYP3A4 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> by 63 % and 37 %, respectively. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode: line"> of dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should </span>outweigh<span style="layout-grid-mode:line"> the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2). </span>Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of <span style="layout-grid-mode:line">aripiprazole</span> should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with <span style="layout-grid-mode:line">aripiprazole</span>, modest increases in plasma aripiprazole concentrations may be expected.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Carbamazepine and other CYP3A4 inducers</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of C<span class="EMEASubscript">max</span> and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when <span style="layout-grid-mode:line">aripiprazole (30 mg) was administered alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span class="EMEASubscript">max</span> and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone.<span style="layout-grid-mode:line"> Aripiprazole</span> dose should be doubled when concomitant administration of <span style="layout-grid-mode:line">aripiprazole</span> occurs with carbamazepine. Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of strong CYP3A4 inducers, the dosage of <span style="layout-grid-mode:line">aripiprazole</span> should be reduced to the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Valproate and lithium</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations </span><span lang="EN-GB">and therefore no dose adjustment is necessary when either valproate or lithium is administered with aripiprazole<span style="color:black">.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for <span style="layout-grid-mode:line">aripiprazole</span> to affect other medicinal products</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism <i>in vitro</i>. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Serotonin syndrome</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.6     Fertility, pregnancy and lactation</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pregnancy</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborn infants should be monitored carefully (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Breast-feeding</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB">Aripiprazole/metabolites are excreted in human milk. <em><span style="font-style:normal">A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from </span></em>aripiprazole<em><span style="font-style:normal"> therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal">Fertility</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB">Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.7     Effects on ability to drive and use machines</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-style:normal">Aripiprazole </span></em><span lang="EN-GB">has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.8     Undesirable effects</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Summary of the safety profile</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3<b> </b>% of patients treated with oral aripiprazole.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Tabulated list of adverse reactions</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as "not known".</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:-1.7pt;border-collapse:collapse;border:none" width="624"> <thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:92.15pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Common</span></b></p> </td> <td style="width:106.3pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Uncommon</span></b></p> </td> <td style="width:163.0pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Not known</span></b></p> </td> </tr> </thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Blood and lymphatic system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Leukopenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Neutropenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Thrombocytopenia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Immune system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Allergic reaction (e.g. anaphylactic   reaction, angioedema including swollen tongue, tongue oedema, face oedema,   pruritus allergic, or urticaria)</span></em></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Endocrine disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperprolactinaemia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="PT" style="color:black">Diabetic hyperosmolar   coma</span></p> <p class="MsoNormal"><span lang="PT" style="color:black">Diabetic ketoacidosis</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Metabolism and nutrition disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-align:justify;text-autospace:none"><span lang="EN-GB" style="color:black">Diabetes mellitus</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Default"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Hyponatremia</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Anorexia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Psychiatric disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Insomnia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Anxiety</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Restlessness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Depression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypersexuality</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Suicide attempt, suicidal ideation and completed suicide   (see section 4.4)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pathological gambling</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Impulse-control   disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Binge eating</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Compulsive   shopping</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Poriomania</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aggression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Agitation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nervousness </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Nervous system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Akathisia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Extrapyramidal disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tremor</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Headache</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sedation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Somnolence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dizziness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dystonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="IT" style="color:black">Restless legs syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Neuroleptic Malignant Syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Grand mal convulsion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Serotonin syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Speech disorder</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Eye disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vision blurred</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diplopia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photophobia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oculogyric crisis</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Cardiac disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tachycardia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sudden death unexplained</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Torsades de pointes</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Ventricular arrhythmia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cardiac arrest</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Bradycardia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Vascular disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Orthostatic hypotension</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Venous thromboembolism (including pulmonary embolism and   deep vein thrombosis)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypertension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Syncope</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Respiratory, thoracic and mediastinal   disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hiccups</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Aspiration pneumonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Laryngospasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oropharyngeal spasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Gastrointestinal disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Constipation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dyspepsia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nausea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Salivary hypersecretion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vomiting</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pancreatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dysphagia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diarrhoea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Abdominal discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stomach discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Hepatobiliary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatic failure</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Jaundice</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rash</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photosensitivity reaction</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alopecia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperhidrosis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Drug Reaction   with Eosinophilia and Systemic Symptoms (DRESS)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Musculoskeletal and connective tissue   disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rhabdomyolysis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Myalgia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stiffness</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Renal and urinary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary incontinence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary retention</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Pregnancy, puerperium and perinatal conditions</span></b></em></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Drug withdrawal syndrome neonatal (see section 4.6)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Reproductive system and breast disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Priapism</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">General disorders and administration   site conditions</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Fatigue</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Temperature regulation disorder (e.g. hypothermia,   pyrexia)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Chest pain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Peripheral oedema</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Investigations</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight gain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alanine Aminotransferase </span><span lang="EN-GB" style="color:black">increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aspartate Aminotransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gamma-glutamyltransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alkaline phosphatase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">QT prolonged</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Glycosylated haemoglobin increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose fluctuation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Creatine phosphokinase increased</span></p> </td> </tr> </table><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Description of selected adverse reactions</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Extrapyramidal symptoms (EPS)</span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia:</span></i><span lang="EN-GB" style="color:black"> in a long-term 52‑week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long-term 26‑week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26‑week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder: </span></i><span lang="EN-GB" style="color:black">in a 12‑week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients. In another 12‑week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long-term 26‑week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Akathisia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dystonia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Prolactin</span></em></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Laboratory parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents aged 15 years and older</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a short-term placebo-controlled clinical trial involving 302 adolescents (13 to 17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Somnolence/sedation and extrapyramidal disorder were reported very commonly (≥ 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (≥ 1/100, &lt; 1/10). The safety profile in a 26‑week open-label extension trial was similar to that observed in the short-term, placebo-controlled trial.</span></p><p class="MsoNormal"><span lang="EN-GB">The safety profile of a long-term, double-blind, placebo-controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (≥ 1/100, &lt; 1/10).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the pooled adolescent schizophrenia population (13 to 17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 29.5 % and 48.3 %, respectively. In the adolescent (13 to 17 years) schizophrenia population with aripiprazole exposure of 5 mg to 30 mg up to 72 months, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 25.6 % and 45.0 %, respectively.</span></p><p class="MsoNormal"><span lang="EN-GB">In two long-term trials with adolescent (13 to 17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 37.0 % and 59.4 %, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The frequency and type of adverse reactions in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (≥ 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (≥ 1/100, &lt; 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %; 30 mg, 28.8 %; placebo, 1.7 %); and akathisia (incidences were 10 mg, 12.1 %; 30 mg, 20.3 %; placebo, 1.7<b> </b>%).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the paediatric bipolar population (10 to 17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 28.0 % and 53.3 %, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see </span><span lang="EN-GB">section 4.4).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Reporting of suspected adverse reactions</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <span style="background:silver">via the national reporting system listed in <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V</a>.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.9     Overdose</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Signs and symptoms</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed </span><span lang="EN-GB" style="color: black">included lethargy, increased blood pressure, somnolence, tachycardia, nausea, </span><span lang="EN-GB" style="color:black">vomiting and diarrhoea. </span><span lang="EN-GB" style="color:black">In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness </span><span lang="EN-GB" style="color:black">and extrapyramidal symptoms</span><span lang="EN-GB" style="color:black">.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Management of overdose</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole C<span class="EMEASubscript">max</span> by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in the treatment of overdose.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Haemodialysis</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">5.       PHARMACOLOGICAL PROPERTIES</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">5.1     Pharmacodynamic properties</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Mechanism of action</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D<sub>2</sub> and serotonin 5‑HT<sub>1A</sub> receptors and antagonism of serotonin 5‑HT<sub>2A</sub> receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in vitro</i> for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5‑HT<sub>1A</sub> and 5‑HT<sub>2A</sub> receptors and moderate affinity for dopamine D<sub>4</sub>, serotonin 5‑HT<sub>2C</sub> and 5‑HT<sub>7</sub>, alpha‑1 adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole doses ranging from 0.5 mg to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to the caudate and putamen detected by positron emission tomography.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Clinical efficacy and safety"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Clinical efficacy and safety</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A<em><span style="font-style:normal">ripiprazole</span></em> is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52‑weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %). The overall completion rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %). Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Åsberg Depression Rating Scale (MADRS) showed a significant improvement over haloperidol.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and 57 % in placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Weight gain</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a 26‑week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Lipid parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Prolactin</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two<b> </b>3‑week, flexible-dose,<b> </b>placebo-controlled monotherapy trials involving<b> </b>patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In one 3‑week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two 12‑week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 6‑week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial, followed by a 74‑week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomisation, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 52‑week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS] and MADRS with total scores ≤ 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores. In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilised for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 6‑week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 to 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo. In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74 % of the total enrolled population, maintenance of effect was observed over the 26‑week open-label extension trial.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB">In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13 to 17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups. The point estimate of the hazard ratio (HR) was 0.461 (95 % confidence interval, 0.242 to 0.879) in the full population. In sub-group analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. However, the estimation of the HR for the younger (13 to 14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (</span><span lang="EN-GB" style="color:black">ranging from 0.151 to 1.628</span><span lang="EN-GB">) did not allow conclusions to be drawn on the presence of a treatment effect. In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in children and adolescents</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was studied in a 30‑week placebo-controlled trial involving 296 children and adolescents (10 to 17 years), who met DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a YMRS score </span><span lang="EN-GB" style="font-family:Symbol;color:black">³</span><span lang="EN-GB" style="color:black"> 20 at baseline. Among the patients included in the primary efficacy analysis, 139 patients had a current co-morbid diagnosis of ADHD.</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. Recurrence prevention was not established.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). Mean weight gain in the 30 weeks treatment-interval was 2.9 kg as compared to 0.98 kg in patients treated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Irritability associated with autistic disorder in paediatric patients (see section 4.2)</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was studied in patients aged 6 to 17 years in two 8‑week, placebo-controlled trials [one flexible-dose (2 mg/day to 15 mg/day) and one fixed-dose (5 mg/day, 10 mg/day, or 15 mg/day)] and in one 52‑week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale. However, the clinical relevance of this finding has not been established. The safety profile included weight gain and changes in prolactin levels. The duration of the long-term safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo-controlled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a 13 to 26‑week stabilisation on aripiprazole (2 mg/day to 15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17 % of patients, with tremor accounting for 6.5<b> </b>%.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Tics associated with Tourette’s disorder in paediatric patients (see section 4.2)</span></i></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>The efficacy of aripiprazole was studied in paediatric subjects with Tourette’s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo-controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg. Patients were 7 to 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35, for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>The efficacy of aripiprazole in paediatric subjects with Tourette’s syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study conducted in South-Korea. Patients were 6 to 18 years and presented an average score of 29 on TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>In both of these short-term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. No long-term data are available with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The European Medicines Agency has deferred the obligation to submit the results of studies with ABILIFY in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">5.2     Pharmacokinetic properties</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Absorption</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3 to 5 hours after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral bioavailability of the tablet formulation is 87 %. There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Distribution"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Distribution</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 L/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Biotransformation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in vitro</i> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40 % of aripiprazole AUC in plasma.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elimination</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The total body clearance of aripiprazole is 0.7 mL/min/kg, which is primarily hepatic.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pharmacokinetics in special patient groups</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Smoking</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation has revealed no evidence of clinically significant <em><span style="font-style:normal">effects from </span></em>smoking on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB" style="color:black">Race</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation showed no evidence of race‑related differences on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Renal impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A single-dose study in subjects with varying degrees of liver cirrhosis (Child‑Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">5.3     Preclinical safety data</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m<span class="EMEASuperscript">2</span>). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39‑week study and are well below (6 %) their limits of <i>in vitro</i> solubility.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.1     List of excipients</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Tablet core</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Maize starch</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hydroxypropyl cellulose</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Magnesium stearate</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="NO-BOK" style="color:black">Tablet coat</span></u></p><p class="EMEABodyText"><span lang="NO-BOK" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="NO-BOK" style="color:black">ABILIFY 5 mg tablets</span></u></p><p class="EMEABodyText"><span lang="NO-BOK" style="color:black">Indigo carmine aluminium lake (E 132)</span></p><p class="EMEABodyText"><span lang="NO-BOK" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="ES" style="color:black">ABILIFY 10 mg tablets</span></u></p><p class="EMEABodyText"><span lang="ES" style="color:black">Red iron oxide (E 172)</span></p><p class="EMEABodyText"><span lang="ES" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 15 mg tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Yellow iron oxide (E 172)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="ES" style="color:black">ABILIFY 30 mg tablets</span></u></p><p class="EMEABodyText"><span lang="ES" style="color:black">Red iron oxide (E 172)</span></p><p class="EMEABodyText"><span lang="ES" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.2     Incompatibilities</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Not applicable.</span></p><p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.3     Shelf life</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">3 years</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.4     Special precautions for storage</span></b></p><p class="EMEABodyText" style="text-align:justify"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Store in the original package in order to protect from moisture.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.5     Nature and contents of container</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aluminium perforated unit dose blisters in cartons of 14 × 1, 28 × 1, 49 × 1, 56 × 1, 98 × 1 tablets.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.6     Special precautions for disposal</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Otsuka Pharmaceutical Netherlands B.V.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Herikerbergweg 292</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">1101 CT, Amsterdam</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Netherlands</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 5 mg tablets</span></u></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/001 (5 mg, 14 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/002 (5 mg, 28 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/003 (5 mg, 49 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/004 (5 mg, 56 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/005 (5 mg, 98 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="EMEABodyText"><span lang="DE" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="DE" style="color:black">ABILIFY 10 mg tablets</span></u></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/006 (10 mg, 14 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/007 (10 mg, 28 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/008 (10 mg, 49 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/009 (10 mg, 56 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/010 (10 mg, 98 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="EMEABodyText"><span lang="DE" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="DE" style="color:black">ABILIFY 15 mg tablets</span></u></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/011 (15 mg, 14 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/012 (15 mg, 28 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/013 (15 mg, 49 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/014 (15 mg, 56 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/015 (15 mg, 98 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="EMEABodyText"><span lang="DE" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="DE" style="color:black">ABILIFY 30 mg tablets</span></u></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/016 (30 mg, 14 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/017 (30 mg, 28 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/018 (30 mg, 49 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="DE" style="font-size:11.0pt;color:black">EU/1/04/276/019 (30 mg, 56 </span><span lang="DE" style="color:black">×</span><span lang="DE" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="MsoCommentText"><span lang="EN-GB" style="font-size:11.0pt;color:black">EU/1/04/276/020 (30 mg, 98 </span><span lang="EN-GB" style="color:black">×</span><span lang="EN-GB" style="font-size:11.0pt;color:black"> 1 tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of first authorisation: 04 June 2004</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of latest renewal: 04 June 2009</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">{MM/YYYY}</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Detailed information on this medicinal product is available on the website of the European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">1.       NAME OF THE MEDICINAL PRODUCT</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 10 mg orodispersible tablets</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 15 mg orodispersible tablets</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 30 mg orodispersible tablets</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 10 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Each orodispersible tablet contains 10 mg of aripiprazole.</span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">3.       PHARMACEUTICAL FORM</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Orodispersible tablet</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 10 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">10 mg: Round and pink, marked with "A" over "640" on one side and "10" on the other.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 15 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">15 mg: Round and yellow, marked with "A" over "641" on one side and "15" on the other.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 30 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">30 mg: Round and pink, marked with "A" over "643" on one side and "30" on the other.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.       CLINICAL PARTICULARS</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.1     Therapeutic indications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.2     Posology and method of administration</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Posology</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia:</span></i><span lang="EN-GB" style="color:black;layout-grid-mode:line"> the recommended starting dose for ABILIFY is 10 mg/day or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black;layout-grid-mode: line">Manic episodes in Bipolar I Disorder:</span></i><span lang="EN-GB" style="color:black"> the recommended starting dose for <span style="layout-grid-mode: line">ABILIFY </span>is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. <span style="layout-grid-mode:line">The maximum daily dose should not exceed 30 mg.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black;layout-grid-mode: line">Recurrence prevention of manic episodes in Bipolar I Disorder</span></i><i><span lang="EN-GB" style="color:black">:</span></i><span lang="EN-GB" style="color:black"> for </span><span lang="EN-GB" style="color:black">preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. </span><span lang="EN-GB" style="color:black">Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents aged 15 years and older</span></i><span lang="EN-GB" style="color:black">: the recommended dose for <span style="layout-grid-mode: line">ABILIFY</span> is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using <span style="layout-grid-mode:line">ABILIFY</span> oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1). ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</span></i><span lang="EN-GB" style="color:black">: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ABILIFY oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1). Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, ABILIFY is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Irritability associated with autistic disorder:</span></i><span lang="EN-GB" style="color: black"> the safety and efficacy of ABILIFY in children and adolescents aged below 18 years have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Tics associated with Tourette’s disorder:</span></i><span lang="EN-GB" style="color:black"> the safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Special populations</span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Renal impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required in patients with renal impairment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The safety and efficacy of ABILIFY in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for female patients as compared to male patients (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Smoking status</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dose adjustments due to interactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Method of administration</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">ABILIFY</span><span lang="EN-GB" style="color:black"> is for oral use.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The orodispersible tablet should be placed in the mouth on the tongue, where it will rapidly disperse in saliva. It can be taken with or without liquid. Removal of the intact orodispersible tablet from the mouth is difficult. Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister. Alternatively, disperse the tablet in water and drink the resulting suspension.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Orodispersible tablets or oral solution may be used as an alternative to ABILIFY tablets for patients who have difficulty swallowing ABILIFY tablets (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.3     Contraindications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.4     Special warnings and precautions for use</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Suicidality</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic <em><span style="font-style:normal">treatment</span></em>, including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients should accompany antipsychotic treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Cardiovascular disorders</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">QT prolongation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Other extrapyramidal symptoms</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In paediatric clinical trials of aripiprazole akathisia and Parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Neuroleptic Malignant Syndrome (NMS)</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Seizure</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elderly patients with dementia-related psychosis</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Increased mortality</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56 to 99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Cerebrovascular adverse reactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78 to 88 years). Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hyperglycaemia and diabetes mellitus</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. Patients treated with any antipsychotics, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hypersensitivity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Weight gain</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Dysphagia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></u></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Aspartame</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY orodispersible tablets contain aspartame. Aspartame is a source of phenylalanine. It may be harmful for people with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Lactose</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY orodispersible tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Sodium</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY orodispersible tablets contain sodium. This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Patients with attention deficit hyperactivity disorder (ADHD) comorbidity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Falls</span></u></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="background:white"><span style="color:black">Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2).</span></p><p class="MsoNormal" style="margin-left:.1pt;text-autospace:none"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.5     Interaction with other medicinal products and other forms of interaction</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">D<span style="layout-grid-mode:line">ue to its α</span><span class="BMSSubscript">1</span>-adrenergic receptor antagonism,<span style="layout-grid-mode:line"> aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for other medicinal products to affect <em><span style="font-style:normal">aripiprazole</span></em></span></u></p><p class="EMEABodyText"><em><u><span lang="EN-GB" style="color:black;font-style: normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A gastric acid blocker, the H<sub>2</sub> antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. <span style="layout-grid-mode:line">Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Quinidine and other CYP2D6 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> was unchanged. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %</span></span><span lang="EN-GB" style="color:black">, respectively</span><span lang="EN-GB" style="color:black;layout-grid-mode:line">. A</span><span lang="EN-GB" style="color:black">ripiprazole<span style="layout-grid-mode:line"> dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of </span>aripiprazole<span style="layout-grid-mode: line"> with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Ketoconazole and other CYP3A4 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> by 63 % and 37 %, respectively. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode: line"> of dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with </span>aripiprazole<span style="layout-grid-mode:line">, potential benefits should </span>outweigh<span style="layout-grid-mode:line"> the potential risks to the patient. When concomitant administration of ketoconazole with </span>aripiprazole<span style="layout-grid-mode:line"> occurs, </span>aripiprazole<span style="layout-grid-mode:line"> dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2).</span> Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Carbamazepine and other CYP3A4 inducers</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of C<span class="EMEASubscript">max</span> and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when <span style="layout-grid-mode:line">aripiprazole (30 mg) was administered alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span class="EMEASubscript">max</span> and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine. Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of strong CYP3A4 inducers, the dosage of aripiprazole should be reduced to the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Valproate and lithium</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations </span><span lang="EN-GB">and therefore no dose adjustment is necessary when either valproate or lithium is administered with aripiprazole<span style="color:black">.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for aripiprazole to affect other medicinal products</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism <i>in vitro</i>. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Serotonin syndrome</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.6     Fertility, pregnancy and lactation</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pregnancy</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborn infants should be monitored carefully (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Breast-feeding</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB">Aripiprazole/metabolites are excreted in human milk. <em><span style="font-style:normal">A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from </span></em>aripiprazole<em><span style="font-style:normal"> therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal">Fertility</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB">Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.7     Effects on ability to drive and use machines</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-style:normal">Aripiprazole </span></em><span lang="EN-GB">has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.8     Undesirable effects</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Summary of the safety profile</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3<b> </b>% of patients treated with oral aripiprazole.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Tabulated list of adverse reactions</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as "not known".</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:-1.7pt;border-collapse:collapse;border:none" width="624"> <thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:92.15pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Common</span></b></p> </td> <td style="width:106.3pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Uncommon</span></b></p> </td> <td style="width:163.0pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Not known</span></b></p> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> </tr> </thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Blood and lymphatic system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Leukopenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Neutropenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Thrombocytopenia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Immune system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Allergic reaction (e.g. anaphylactic   reaction, angioedema including swollen tongue, tongue oedema, face oedema,   pruritus allergic, or urticaria)</span></em></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Endocrine disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperprolactinaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Diabetic hyperosmolar   coma</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Diabetic ketoacidosis</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Metabolism and nutrition disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-align:justify;text-autospace:none"><span lang="EN-GB" style="color:black">Diabetes mellitus</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Default"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Hyponatremia</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Anorexia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Psychiatric disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Insomnia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Anxiety</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Restlessness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Depression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypersexuality</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Suicide attempt, suicidal ideation and completed suicide   (see section 4.4)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pathological gambling</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Impulse-control   disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Binge eating</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Compulsive   shopping</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Poriomania</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aggression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Agitation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nervousness </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Nervous system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Akathisia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Extrapyramidal disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tremor</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Headache</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sedation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Somnolence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dizziness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dystonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="IT" style="color:black">Restless legs syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Neuroleptic Malignant Syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Grand mal convulsion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Serotonin syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Speech disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Eye disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vision blurred</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diplopia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photophobia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oculogyric crisis</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Cardiac disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tachycardia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sudden death unexplained </span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Torsades de pointes</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Ventricular arrhythmia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cardiac arrest</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Bradycardia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Vascular disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Orthostatic hypotension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Venous thromboembolism (including pulmonary embolism and   deep vein thrombosis)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypertension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Syncope</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Respiratory, thoracic and mediastinal   disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hiccups</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Aspiration pneumonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Laryngospasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oropharyngeal spasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Gastrointestinal disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Constipation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dyspepsia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nausea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Salivary hypersecretion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vomiting</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pancreatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dysphagia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diarrhoea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Abdominal discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stomach discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Hepatobiliary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatic failure</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Jaundice</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rash</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photosensitivity reaction</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alopecia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperhidrosis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Drug Reaction   with Eosinophilia and Systemic Symptoms (DRESS)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Musculoskeletal and connective tissue   disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rhabdomyolysis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Myalgia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stiffness</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Renal and urinary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary incontinence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary retention</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Pregnancy, puerperium and perinatal conditions</span></b></em></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Drug withdrawal syndrome neonatal (see section 4.6)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Reproductive system and breast disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Priapism</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">General disorders and administration   site conditions</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Fatigue</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Temperature regulation disorder (e.g. hypothermia,   pyrexia)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Chest pain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Peripheral oedema</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Investigations</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight gain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alanine Aminotransferase </span><span lang="EN-GB" style="color:black">increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aspartate Aminotransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gamma-glutamyltransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alkaline phosphatase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">QT prolonged</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Glycosylated haemoglobin increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose fluctuation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Creatine phosphokinase increased</span></p> </td> </tr> </table><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Description of selected adverse reactions</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Extrapyramidal symptoms (EPS)</span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia:</span></i><span lang="EN-GB" style="color:black"> in a long-term 52‑week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long-term 26‑week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26‑week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder: </span></i><span lang="EN-GB" style="color:black">in a 12‑week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients. In another 12‑week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long-term 26‑week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Akathisia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dystonia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Prolactin</span></em></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Laboratory parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents aged 15 years and older</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a short-term placebo-controlled clinical trial involving 302 adolescents (13 to 17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Somnolence/sedation and extrapyramidal disorder were reported very commonly (≥ 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (≥ 1/100, &lt; 1/10). The safety profile in a 26‑week open-label extension trial was similar to that observed in the short-term, placebo-controlled trial.</span></p><p class="MsoNormal"><span lang="EN-GB">The safety profile of a long-term, double-blind, placebo-controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (≥ 1/100, &lt; 1/10).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the pooled adolescent schizophrenia population (13 to 17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 29.5 % and 48.3 %, respectively. In the adolescent (13 to 17 years) schizophrenia population with aripiprazole exposure of 5 mg to 30 mg up to 72 months, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 25.6 % and 45.0 %, respectively.</span></p><p class="MsoNormal"><span lang="EN-GB">In two long-term trials with adolescent (13 to 17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 37.0 % and 59.4 %, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The frequency and type of adverse reactions in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (≥ 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (≥ 1/100, &lt; 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %; 30 mg, 28.8 %; placebo, 1.7 %); and akathisia (incidences were 10 mg, 12.1 %; 30 mg, 20.3 %; placebo, 1.7<b> </b>%).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the paediatric bipolar population (10 to 17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 28.0 % and 53.3 %, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see </span><span lang="EN-GB">section 4.4).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Reporting of suspected adverse reactions</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <span style="background:silver">via the national reporting system listed in <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V</a>.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.9     Overdose</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Signs and symptoms</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed </span><span lang="EN-GB" style="color: black">included lethargy, increased blood pressure, somnolence, tachycardia, nausea, </span><span lang="EN-GB" style="color:black">vomiting and diarrhoea. </span><span lang="EN-GB" style="color:black">In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness </span><span lang="EN-GB" style="color:black">and extrapyramidal symptoms</span><span lang="EN-GB" style="color:black">.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Management of overdose</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole C<span class="EMEASubscript">max</span> by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in the treatment of overdose.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Haemodialysis</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">5.       PHARMACOLOGICAL PROPERTIES</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">5.1     Pharmacodynamic properties</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Mechanism of action</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D<sub>2</sub> and serotonin 5‑HT<sub>1A</sub> receptors and antagonism of serotonin 5‑HT<sub>2A</sub> receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in vitro</i> for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5‑HT<sub>1A</sub> and 5‑HT<sub>2A</sub> receptors and moderate affinity for dopamine D<sub>4</sub>, serotonin 5‑HT<sub>2C</sub> and 5‑HT<sub>7</sub>, alpha‑1 adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole doses ranging from 0.5 mg to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to the caudate and putamen detected by positron emission tomography.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Clinical efficacy and safety"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Clinical efficacy and safety</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52‑weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %). The overall completion rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %). Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Åsberg Depression Rating Scale (MADRS) showed a significant improvement over haloperidol.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and 57 % in placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Weight gain</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a 26‑week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Lipid parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Prolactin</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two<b> </b>3‑week, flexible-dose,<b> </b>placebo-controlled monotherapy trials involving<b> </b>patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In one 3‑week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two 12‑week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 6‑week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial, followed by a 74‑week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomisation, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 52‑week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS] and MADRS with total scores ≤ 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores. In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilised for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 6‑week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 to 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo. In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74 % of the total enrolled population, maintenance of effect was observed over the 26‑week open-label extension trial.</span></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p><p class="EMEABodyText"><span lang="EN-GB">In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13 to 17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups. The point estimate of the hazard ratio (HR) was 0.461 (95 % confidence interval, 0.242 to 0.879) in the full population. In subgroup analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. However, the estimation of the HR for the younger (13 to 14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (</span><span lang="EN-GB" style="color:black">ranging from 0.151 to 1.628</span><span lang="EN-GB">) did not allow conclusions to be drawn on the presence of a treatment effect. In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in children and adolescents</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was studied in a 30‑week placebo-controlled trial involving 296 children and adolescents (10 to 17 years), who met DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a YMRS score </span><span lang="EN-GB" style="font-family:Symbol;color:black">³</span><span lang="EN-GB" style="color:black"> 20 at baseline. Among the patients included in the primary efficacy analysis, 139 patients had a current co-morbid diagnosis of ADHD.</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. Recurrence prevention was not established.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). Mean weight gain in the 30 weeks treatment-interval was 2.9 kg as compared to 0.98 kg in patients treated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Irritability associated with autistic disorder in paediatric patients (see section 4.2)</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was studied in patients aged 6 to 17 years in two 8‑week, placebo-controlled trials [one flexible-dose (2 mg/day to 15 mg/day) and one fixed-dose (5 mg/day, 10 mg/day, or 15 mg/day)] and in one 52‑week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale. However, the clinical relevance of this finding has not been established. The safety profile included weight gain and changes in prolactin levels. The duration of the long-term safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo-controlled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a 13 to 26‑week stabilisation on aripiprazole (2 mg/day to 15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17 % of patients, with tremor accounting for 6.5<b> </b>%.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Tics associated with Tourette’s disorder in paediatric patients (see section 4.2)</span></i></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>The efficacy of aripiprazole was studied in paediatric subjects with Tourette’s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg. Patients were 7 to 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35, for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>The efficacy of aripiprazole in paediatric subjects with Tourette’s syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study conducted in South-Korea. Patients were 6 to 18 years and presented an average score of 29 on TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>In both of these short-term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. No long-term data are available with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The European Medicines Agency has deferred the obligation to submit the results of studies with ABILIFY in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">5.2     Pharmacokinetic properties</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Absorption</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3 to 5 hours after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral bioavailability of the tablet formulation is 87 %. There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Distribution"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Distribution</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 L/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Biotransformation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in vitro</i> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40 % of aripiprazole AUC in plasma.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elimination</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The total body clearance of aripiprazole is 0.7 mL/min/kg, which is primarily hepatic.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pharmacokinetics in special patient groups</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Smoking</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation has revealed no evidence of clinically significant <em><span style="font-style:normal">effects from </span></em>smoking on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB" style="color:black">Race</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation showed no evidence of race‑related differences on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Renal impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A single-dose study in subjects with varying degrees of liver cirrhosis (Child‑Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">5.3     Preclinical safety data</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m<span class="EMEASuperscript">2</span>). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39‑week study and are well below (6 %) their limits of <i>in vitro</i> solubility.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.1     List of excipients</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Tablet core</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Calcium silicate</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Croscarmellose sodium</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Crospovidone</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Silicon dioxide</span></p><p class="EMEABodyText"><span lang="IT" style="color:black">Xylitol</span></p><p class="EMEABodyText"><span lang="IT" style="color:black">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="IT" style="color:black">Aspartame (E 951)</span></p><p class="EMEABodyText"><span lang="IT" style="color:black">Acesulfame potassium</span></p><p class="EMEABodyText"><span lang="IT" style="color:black">Vanilla flavour (including vanillin, ethyl vanillin and lactose)</span></p><p class="EMEABodyText"><span lang="IT" style="color:black">Tartaric acid</span></p><p class="EMEABodyText"><span lang="IT" style="color:black">Magnesium stearate</span></p><p class="EMEABodyText"><span lang="IT" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="IT" style="color:black">Tablet coat</span></u></p><p class="EMEABodyText"><u><span lang="IT" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="IT" style="color:black">ABILIFY 10 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="IT" style="color:black">Red iron oxide (E 172)</span></p><p class="EMEABodyText"><span lang="IT" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="IT" style="color:black">ABILIFY 15 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="IT" style="color:black">Yellow iron oxide (E 172)</span></p><p class="EMEABodyText"><span lang="IT" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="ES" style="color:black">ABILIFY 30 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="ES" style="color:black">Red iron oxide (E 172)</span></p><p class="EMEABodyText"><span lang="ES" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.2     Incompatibilities</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Not applicable.</span></p><p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.3     Shelf life</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">3 years</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.4     Special precautions for storage</span></b></p><p class="EMEABodyText" style="text-align:justify"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Store in the original package in order to protect from moisture.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.5     Nature and contents of container</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aluminium perforated unit dose blisters in cartons of 14 × 1, 28 × 1, 49 × 1 tablets.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.6     Special precautions for disposal</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Otsuka Pharmaceutical Netherlands B.V.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Herikerbergweg 292</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">1101 CT, Amsterdam</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Netherlands</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 10 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/024 (10 mg, 14 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/025 (10 mg, 28 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/026 (10 mg, 49 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 15 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/027 (15 mg, 14 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/028 (15 mg, 28 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/029 (15 mg, 49 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">ABILIFY 30 mg orodispersible tablets</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/030 (30 mg, 14 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/031 (30 mg, 28 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/032 (30 mg, 49 × 1 orodispersible tablets)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of first authorisation: 04 June 2004</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of latest renewal: 04 June 2009</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">{MM/YYYY}</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Detailed information on this medicinal product is available on the website of the European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p><p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black"> </span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">1.       NAME OF THE MEDICINAL PRODUCT</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 1 mg/mL oral solution</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Each mL oral solution contains 1 mg of aripiprazole.</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Excipients with known effect (per mL)</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">200 mg fructose, 400 mg sucrose, 1.8 mg methyl parahydroxybenzoate (E218), 0.2 mg propyl parahydroxybenzoate (E 216)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">3.       PHARMACEUTICAL FORM</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Oral solution</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Clear, colourless to light yellow liquid solution.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.       CLINICAL PARTICULARS</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.1     Therapeutic indications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.2     Posology and method of administration</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Posology</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia:</span></i><span lang="EN-GB" style="color:black;layout-grid-mode:line"> the recommended starting dose for ABILIFY is 10 mg/day or 15 mg/day (i.e. 10 mL or 15 mL solution/day) with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day (i.e. 10 mL to 30 mL solution/day). Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black;layout-grid-mode: line">Manic episodes in Bipolar I Disorder:</span></i><span lang="EN-GB" style="color:black"> the recommended starting dose for <span style="layout-grid-mode: line">ABILIFY </span>is 15 mg (i.e. 15 mL solution/day) administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. <span style="layout-grid-mode:line">The maximum daily dose should not exceed 30 mg.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black;layout-grid-mode: line">Recurrence prevention of manic episodes in Bipolar I Disorder</span></i><i><span lang="EN-GB" style="color:black">:</span></i><span lang="EN-GB" style="color:black"> for </span><span lang="EN-GB" style="color:black">preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. </span><span lang="EN-GB" style="color:black">Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents aged 15 years and older</span></i><span lang="EN-GB" style="color:black">: the recommended dose for <span style="layout-grid-mode: line">ABILIFY</span> is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using <span style="layout-grid-mode:line">ABILIFY</span> oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1). ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</span></i><span lang="EN-GB" style="color:black">: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ABILIFY oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1). Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, ABILIFY is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Irritability associated with autistic disorder:</span></i><span lang="EN-GB" style="color: black"> the safety and efficacy of ABILIFY in children and adolescents aged below 18 years have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Tics associated with Tourette’s disorder:</span></i><span lang="EN-GB" style="color:black"> the safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Special populations</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Renal impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required in patients with renal impairment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The safety and efficacy of ABILIFY in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for female patients as compared to male patients (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Smoking status</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dose adjustments due to interactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Method of administration</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">ABILIFY</span><span lang="EN-GB" style="color:black"> is for oral use.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Orodispersible tablets or oral solution may be used as an alternative to ABILIFY tablets for patients who have difficulty swallowing ABILIFY tablets (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.3     Contraindications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.4     Special warnings and precautions for use</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Suicidality</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic <em><span style="font-style:normal">treatment</span></em>, including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients should accompany antipsychotic treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Cardiovascular disorders</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">QT prolongation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Other extrapyramidal symptoms</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In paediatric clinical trials of aripiprazole akathisia and Parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Neuroleptic Malignant Syndrome (NMS)</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Seizure</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elderly patients with dementia-related psychosis</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Increased mortality</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56 to 99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Cerebrovascular adverse reactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78 to 88 years). Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hyperglycaemia and diabetes mellitus</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. Patients treated with any antipsychotics, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hypersensitivity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Weight gain</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Dysphagia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></u></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Fructose and sucrose</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The oral solution contains fructose and sucrose. Fructose may damage teeth. Sucrose may be harmful to the teeth. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Parahydroxybenzoate</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate. May cause allergic reactions (possibly delayed).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Sodium</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The oral solution contains sodium. This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Patients with attention deficit hyperactivity disorder (ADHD) comorbidity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Falls</span></u></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="background:white"><span style="color:black">Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">4.5     Interaction with other medicinal products and other forms of interaction</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">D<span style="layout-grid-mode:line">ue to its α</span><span class="BMSSubscript">1</span>-adrenergic receptor antagonism,<span style="layout-grid-mode:line"> aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for other medicinal products to affect aripiprazole</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A gastric acid blocker, the H<sub>2</sub> antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. <span style="layout-grid-mode:line">Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Quinidine and other CYP2D6 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> was unchanged. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %</span></span><span lang="EN-GB" style="color:black">, respectively</span><span lang="EN-GB" style="color:black;layout-grid-mode:line">. A</span><span lang="EN-GB" style="color:black">ripiprazole<span style="layout-grid-mode:line"> dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of </span>aripiprazole<span style="layout-grid-mode: line"> with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Ketoconazole and other CYP3A4 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> by 63 % and 37 %, respectively. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode: line"> of dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with </span>aripiprazole<span style="layout-grid-mode:line">, potential benefits should </span>outweigh<span style="layout-grid-mode:line"> the potential risks to the patient. When concomitant administration of ketoconazole with </span>aripiprazole<span style="layout-grid-mode:line"> occurs, </span>aripiprazole<span style="layout-grid-mode:line"> dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2).</span> Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Carbamazepine and other CYP3A4 inducers</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of C<span class="EMEASubscript">max</span> and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when <span style="layout-grid-mode:line">aripiprazole (30 mg) was administered alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span class="EMEASubscript">max</span> and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine. Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of strong CYP3A4 inducers, the dosage of aripiprazole should be reduced to the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Valproate and lithium</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations </span><span lang="EN-GB">and therefore no dose adjustment is necessary when either valproate or lithium is administered with aripiprazole<span style="color:black">.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for aripiprazole to affect other medicinal products</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism <i>in vitro</i>. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Serotonin syndrome</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.6     Fertility, pregnancy and lactation</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pregnancy</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborn infants should be monitored carefully (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Breast-feeding</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole/</span><span lang="EN-GB">metabolites are<span style="color:black"> excreted in human milk. </span><em><span style="font-style:normal">A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from </span></em>aripiprazole<em><span style="font-style:normal"> therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal">Fertility</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB">Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.7     Effects on ability to drive and use machines</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-style:normal">Aripiprazole </span></em><span lang="EN-GB">has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.8     Undesirable effects</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Summary of the safety profile</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3<b> </b>% of patients treated with oral aripiprazole.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Tabulated list of adverse reactions</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as "not known".</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:-1.7pt;border-collapse:collapse;border:none" width="624"> <thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:92.15pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Common</span></b></p> </td> <td style="width:106.3pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Uncommon</span></b></p> </td> <td style="width:163.0pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Not known</span></b></p> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> </tr> </thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Blood and lymphatic system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Leukopenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Neutropenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Thrombocytopenia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Immune system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Allergic reaction (e.g. anaphylactic   reaction, angioedema including swollen tongue, tongue oedema, face oedema,   pruritus allergic, or urticaria)</span></em></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Endocrine disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperprolactinaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Diabetic hyperosmolar   coma</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Diabetic ketoacidosis</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Metabolism and nutrition disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-align:justify;text-autospace:none"><span lang="EN-GB" style="color:black">Diabetes mellitus</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Default"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Hyponatremia</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Anorexia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Psychiatric disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Insomnia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Anxiety</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Restlessness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Depression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypersexuality</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Suicide attempt, suicidal ideation and completed suicide   (see section 4.4)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pathological gambling</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Impulse-control   disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Binge eating</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Compulsive   shopping</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Poriomania</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aggression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Agitation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nervousness </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Nervous system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Akathisia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Extrapyramidal disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tremor</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Headache</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sedation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Somnolence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dizziness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dystonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="IT" style="color:black">Restless legs syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Neuroleptic Malignant Syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Grand mal convulsion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Serotonin syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Speech disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Eye disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vision blurred</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diplopia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photophobia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oculogyric crisis</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Cardiac disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tachycardia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sudden death unexplained </span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Torsades de pointes</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Ventricular arrhythmia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cardiac arrest</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Bradycardia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Vascular disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Orthostatic hypotension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Venous thromboembolism (including pulmonary embolism and   deep vein thrombosis)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypertension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Syncope</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Respiratory, thoracic and mediastinal   disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hiccups</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Aspiration pneumonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Laryngospasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oropharyngeal spasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Gastrointestinal disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Constipation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dyspepsia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nausea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Salivary hypersecretion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vomiting</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pancreatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dysphagia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diarrhoea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Abdominal discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stomach discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Hepatobiliary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatic failure</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Jaundice</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rash</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photosensitivity reaction</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alopecia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperhidrosis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Drug Reaction   with Eosinophilia and Systemic Symptoms (DRESS)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Musculoskeletal and connective tissue   disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rhabdomyolysis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Myalgia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stiffness</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Renal and urinary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary incontinence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary retention</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Pregnancy, puerperium and perinatal conditions</span></b></em></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Drug withdrawal syndrome neonatal (see section 4.6)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Reproductive system and breast disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Priapism</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">General disorders and administration   site conditions</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Fatigue</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Temperature regulation disorder (e.g. hypothermia,   pyrexia)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Chest pain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Peripheral oedema</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Investigations</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight gain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alanine Aminotransferase </span><span lang="EN-GB" style="color:black">increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aspartate Aminotransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gamma-glutamyltransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alkaline phosphatase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">QT prolonged</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Glycosylated haemoglobin increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose fluctuation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Creatine phosphokinase increased</span></p> </td> </tr> </table><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Description of selected adverse reactions</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Extrapyramidal symptoms (EPS)</span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia:</span></i><span lang="EN-GB" style="color:black"> in a long-term 52‑week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long-term 26‑week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26‑week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder: </span></i><span lang="EN-GB" style="color:black">in a 12‑week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients. In another 12‑week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long-term 26‑week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Akathisia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dystonia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Prolactin</span></em></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Laboratory parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents aged 15 years and older</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a short-term placebo-controlled clinical trial involving 302 adolescents (13 to 17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Somnolence/sedation and extrapyramidal disorder were reported very commonly (≥ 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (≥ 1/100, &lt; 1/10). The safety profile in a 26‑week open-label extension trial was similar to that observed in the short-term, placebo-controlled trial.</span></p><p class="MsoNormal"><span lang="EN-GB">The safety profile of a long-term, double-blind, placebo-controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (≥ 1/100, &lt; 1/10).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the pooled adolescent schizophrenia population (13 to 17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 29.5 % and 48.3 %, respectively. In the adolescent (13 to 17 years) schizophrenia population with aripiprazole exposure of 5 mg to 30 mg up to 72 months, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 25.6 % and 45.0 %, respectively.</span></p><p class="MsoNormal"><span lang="EN-GB">In two long-term trials with adolescent (13 to 17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 37.0 % and 59.4 %, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The frequency and type of adverse reactions in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (≥ 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (≥ 1/100, &lt; 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %; 30 mg, 28.8 %; placebo, 1.7 %); and akathisia (incidences were 10 mg, 12.1 %; 30 mg, 20.3 %; placebo, 1.7<b> </b>%).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the paediatric bipolar population (10 to 17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 28.0 % and 53.3 %, respectively.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see </span><span lang="EN-GB">section 4.4).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Reporting of suspected adverse reactions</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <span style="background:silver">via the national reporting system listed in <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V</a>.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">4.9     Overdose</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Signs and symptoms</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed </span><span lang="EN-GB" style="color: black">included lethargy, increased blood pressure, somnolence, tachycardia, nausea, </span><span lang="EN-GB" style="color:black">vomiting and diarrhoea. </span><span lang="EN-GB" style="color:black">In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness </span><span lang="EN-GB" style="color:black">and extrapyramidal symptoms</span><span lang="EN-GB" style="color:black">.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Management of overdose</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole C<span class="EMEASubscript">max</span> by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in the treatment of overdose.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Haemodialysis</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">5.       PHARMACOLOGICAL PROPERTIES</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black">5.1     Pharmacodynamic properties</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Mechanism of action</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D<sub>2</sub> and serotonin 5‑HT<sub>1A</sub> receptors and antagonism of serotonin 5‑HT<sub>2A</sub> receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in vitro</i> for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5‑HT<sub>1A</sub> and 5‑HT<sub>2A</sub> receptors and moderate affinity for dopamine D<sub>4</sub>, serotonin 5‑HT<sub>2C</sub> and 5‑HT<sub>7</sub>, alpha‑1 adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole doses ranging from 0.5 mg to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to the caudate and putamen detected by positron emission tomography.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Clinical efficacy and safety"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Clinical efficacy and safety</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Adults</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A<em><span style="font-style:normal">ripiprazole</span></em> is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52‑weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %). The overall completion rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %). Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Åsberg Depression Rating Scale (MADRS) showed a significant improvement over haloperidol.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and 57 % in placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Weight gain</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a 26‑week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Lipid parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL).</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Prolactin</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two<b> </b>3‑week, flexible-dose,<b> </b>placebo-controlled monotherapy trials involving<b> </b>patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In one 3‑week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two 12‑week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 6‑week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial, followed by a 74‑week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomisation, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 52‑week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS] and MADRS with total scores ≤ 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores. In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilised for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia in adolescents</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 6‑week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 to 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo. In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74 % of the total enrolled population, maintenance of effect was observed over the 26‑week open-label extension trial.</span></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p><p class="EMEABodyText"><span lang="EN-GB">In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13 to 17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups. The point estimate of the hazard ratio (HR) was 0.461 (95 % confidence interval, 0.242 to 0.879) in the full population. In subgroup analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. However, the estimation of the HR for the younger (13 to 14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (</span><span lang="EN-GB" style="color:black">ranging from 0.151 to 1.628</span><span lang="EN-GB">) did not allow conclusions to be drawn on the presence of a treatment effect. In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder in children and adolescents</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was studied in a 30‑week placebo-controlled trial involving 296 children and adolescents (10 to 17 years), who met DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a YMRS score </span><span lang="EN-GB" style="font-family:Symbol;color:black">³</span><span lang="EN-GB" style="color:black"> 20 at baseline. Among the patients included in the primary efficacy analysis, 139 patients had a current co-morbid diagnosis of ADHD.</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. Recurrence prevention was not established.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). Mean weight gain in the 30 weeks treatment-interval was 2.9 kg as compared to 0.98 kg in patients treated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Irritability associated with autistic disorder in paediatric patients (see section 4.2)</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was studied in patients aged 6 to 17 years in two 8‑week, placebo-controlled trials [one flexible-dose (2 mg/day to 15 mg/day) and one fixed-dose (5 mg/day, 10 mg/day, or 15 mg/day)] and in one 52‑week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale. However, the clinical relevance of this finding has not been established. The safety profile included weight gain and changes in prolactin levels. The duration of the long-term safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo-controlled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a 13 to 26‑week stabilisation on aripiprazole (2 mg/day to 15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17 % of patients, with tremor accounting for 6.5<b> </b>%.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Tics associated with Tourette’s disorder in paediatric patients (see section 4.2)</span></i></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>The efficacy of aripiprazole was studied in paediatric subjects with Tourette’s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg. Patients were 7 to 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35, for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>The efficacy of aripiprazole in paediatric subjects with Tourette’s syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study conducted in South-Korea. Patients were 6 to 18 years and presented an average score of 29 on TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'> </span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>In both of these short-term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. No long-term data are available with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The European Medicines Agency has deferred the obligation to submit the results of studies with ABILIFY in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">5.2     Pharmacokinetic properties</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Absorption</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3 to 5 hours after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral bioavailability of the tablet formulation is 87 %. There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Distribution"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Distribution</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 L/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Biotransformation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in vitro</i> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40 % of aripiprazole AUC in plasma.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elimination</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The total body clearance of aripiprazole is 0.7 mL/min/kg, which is primarily hepatic.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Oral Solution</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is well absorbed when administered orally as the solution. At equivalent doses, the peak plasma concentrations of aripiprazole (</span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span></span><span lang="EN-GB" style="color:black">) from the solution were somewhat higher but the systemic exposure (AUC) was equivalent to tablets. In a relative bioavailability study comparing the pharmacokinetics of 30</span><i><span lang="EN-GB" style="color:black"> </span></i><span lang="EN-GB" style="color:black">mg aripiprazole as the oral solution to 30</span><i><span lang="EN-GB" style="color:black"> </span></i><span lang="EN-GB" style="color:black">mg aripiprazole tablets in healthy subjects, the solution to the tablet ratio of geometric mean </span><span lang="EN-GB" style="color: black">C<span class="EMEASubscript">max</span></span><span lang="EN-GB" style="color:black"> values was 122 % (n = 30). The single-dose pharmacokinetics of aripiprazole was linear and dose-proportional.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pharmacokinetics in special patient groups</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Smoking</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation has revealed no evidence of clinically significant <em><span style="font-style:normal">effects from </span></em>smoking on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB" style="color:black">Race</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation showed no evidence of race‑related differences on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Renal impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A single-dose study in subjects with varying degrees of liver cirrhosis (Child‑Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">5.3     Preclinical safety data</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m<span class="EMEASuperscript">2</span>). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39‑week study and are well below (6 %) their limits of <i>in vitro</i> solubility.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.1     List of excipients</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Disodium edetate</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Fructose</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Glycerin</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Lactic acid</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Methyl parahydroxybenzoate (E 218)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Propylene glycol</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Propyl parahydroxybenzoate (E 216)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Sodium hydroxide</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Sucrose</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Purified water</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Orange flavour</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.2     Incompatibilities</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The <span style="layout-grid-mode:line">oral solution should not be diluted with other liquids or mixed with any food prior to administration.</span></span></p><p class="EMEAHeading2" style="page-break-after:auto"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.3     Shelf life</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">3 years</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">After first opening: 6 months.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.4     Special precautions for storage</span></b></p><p class="EMEABodyText" style="text-align:justify"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">This medicinal product does not require any special storage conditions.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">For storage conditions after first opening of the medicinal product, see section 6.3.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.5     Nature and contents of container</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">PET-bottles with polypropylene child-resistant closure containing 50 mL, 150 mL or 480 mL per bottle.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Each carton contains 1 bottle and both a calibrated polypropylene measuring cup </span><span lang="EN" style="color:black">with a graduation interval of 2.5 mL</span><span lang="EN" style="color:black"> </span><span lang="EN-GB" style="color:black">and a calibrated polypropylene low-density polyethylene <a name="_Hlk11317764">dropping pipette</a></span><span lang="EN-GB" style="color:black"> </span><span lang="EN" style="color:black">with a graduation interval of 0.5 mL</span><span lang="EN-GB" style="color:black">.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.6     Special precautions for disposal</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Otsuka Pharmaceutical Netherlands B.V.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Herikerbergweg 292</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">1101 CT, Amsterdam</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Netherlands</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="SV" style="color:black">EU/1/04/276/033 (1 mg/mL, 50 mL per bottle)</span></p><p class="EMEABodyText"><span lang="SV" style="color:black">EU/1/04/276/034 (1 mg/mL, 150 mL per bottle)</span></p><p class="EMEABodyText"><span lang="SV" style="color:black">EU/1/04/276/035 (1 mg/mL, 480 mL per bottle)</span></p><p class="EMEABodyText"><span lang="SV" style="color:black"> </span></p><p class="EMEABodyText"><span lang="SV" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of first authorisation: 04 June 2004</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of latest renewal: 04 June 2009</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">{MM/YYYY}</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Detailed information on this medicinal product is available on the website of the European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p><p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black"> </span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black;text-transform:uppercase'><br clear="all" style="page-break-before: always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black;text-transform:uppercase'><br clear="all" style="page-break-before: always"/> </span><br clear="all" style="page-break-before: always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black;text-transform:uppercase">1.       NAME OF THE MEDICINAL PRODUCT</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY 7.5 mg/mL solution for injection</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Each mL contains 7.5 mg of aripiprazole. Each vial contains 9.75 mg aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">3.       PHARMACEUTICAL FORM</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Solution for injection</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Clear, colourless, aqueous solution.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.       CLINICAL PARTICULARS</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.1     Therapeutic indications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY solution for injection is indicated for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder, when oral therapy is not appropriate.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Treatment with ABILIFY solution for injection should be discontinued as soon as clinically appropriate and the use of oral aripiprazole should be initiated.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.2     Posology and method of administration</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Posology</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The recommended initial dose for ABILIFY solution for injection is 9.75 mg (1.3 mL), administered as a single intramuscular injection. The effective dose range of ABILIFY solution for injection is 5.25 mg to 15 mg as a single injection. A lower dose of 5.25 mg (0.7 mL) may be given, on the basis of individual clinical status, which should also include consideration of medicinal products already administered either for maintenance or acute treatment (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A second injection may be administered 2 hours after the first injection, on the basis of individual clinical status and no more than three injections should be given in any 24-hour period.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The maximum daily dose of aripiprazole is 30 mg (including all formulations of ABILIFY).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">If continued treatment is indicated with oral aripiprazole, see the Summary of Product Characteristics for ABILIFY tablets, ABILIFY orodispersible tablets, or ABILIFY oral solution.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Special populations</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Paediatric population</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">The safety and efficacy of ABILIFY solution for injection in children and adolescents aged 0 to 17 years have not been established. No data are available.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">R<i>enal impairment</i></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required in patients with renal impairment.</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The safety and efficacy of ABILIFY </span><span lang="EN-GB">in the treatment of schizophrenia or manic episodes in Bipolar I Disorder<span style="color:black"> in patients aged 65</span></span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">4.4).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">No dosage adjustment is required for female patients as compared to male patients (see section 5.2).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Smoking status</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">According to the metabolic pathway of <span style="layout-grid-mode:line">aripiprazole </span>no dosage adjustment is required for smokers (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dose adjustments due to interactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Method of administration</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY solution for injection is for intramuscular use.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">To enhance absorption and minimise variability, injection into the deltoid or deep within the gluteus maximus muscle, avoiding adipose regions, is recommended.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY solution for injection should not be administered intravenously or subcutaneously.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">It is ready to use and intended for short-term use only (see section</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">5.1).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.3     Contraindications</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.4     Special warnings and precautions for use</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The efficacy of ABILIFY solution for injection in patients with agitation and disturbed behaviours has not been established related to conditions other than schizophrenia and manic episodes in Bipolar I Disorder.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Simultaneous administration of injectable antipsychotics and parenteral benzodiazepine may be associated with excessive sedation and cardiorespiratory depression. If parenteral benzodiazepine therapy is deemed necessary in addition to aripiprazole solution for injection, patients should be monitored for excessive sedation and for orthostatic hypotension (see section</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">4.5).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Patients receiving ABILIFY solution for injection should be observed for orthostatic hypotension. Blood pressure, pulse, respiratory rate and level of consciousness should be monitored regularly.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The safety and efficacy of ABILIFY solution for injection has not been evaluated in patients with alcohol or medicinal product intoxication (either with prescribed or illicit medicinal products).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Suicidality</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic <em><span style="font-style:normal">treatment</span></em>, including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients should accompany antipsychotic treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Cardiovascular disorders</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">QT prolongation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of treatment with oral aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on <em><span style="font-style:normal">aripiprazole</span></em>, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Other extrapyramidal symptoms</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In paediatric clinical trials of aripiprazole akathisia and Parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Neuroleptic Malignant Syndrome (NMS)</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Seizure</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elderly patients with dementia-related psychosis</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Increased mortality</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three placebo-controlled trials (n = 938; mean age: 82.4</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">years; range: 56 to 99</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">4.8).</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Cerebrovascular adverse reactions</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">years; range: 78 to 88</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">years). Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hyperglycaemia and diabetes mellitus</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics</span><span lang="EN-GB" style="color:black">, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. Patients treated with any antipsychotics, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Hypersensitivity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Weight gain</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed oral aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Dysphagia</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></u></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Sodium</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">ABILIFY solution for injection contains sodium. This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Patients with attention deficit hyperactivity disorder (ADHD) comorbidity</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Falls</span></u></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="background:white"><span style="color:black">Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2).</span></p><p class="EMEABodyText"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.5     Interaction with other medicinal products and other forms of interaction</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">No specific interaction studies have been performed with ABILIFY solution for injection. The information below is obtained from studies with oral aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">D<span style="layout-grid-mode:line">ue to its α</span><span class="BMSSubscript">1</span>-adrenergic receptor antagonism,<span style="layout-grid-mode:line"> aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for other medicinal products to affect ABILIFY solution for injection</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The administration of lorazepam solution for injection had no effect on the pharmacokinetics of ABILIFY solution for injection when administered concomitantly. However, in a single-dose, intramuscular study of aripiprazole (dose 15 mg) in healthy subjects, administered simultaneously with intramuscular lorazepam (dose 2 mg), the intensity of sedation was greater with the combination as compared to that observed with aripiprazole alone.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A gastric acid blocker, the H<sub>2</sub> antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant.<span style="layout-grid-mode:line"> Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Quinidine and other CYP2D6 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> was unchanged. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %</span><em><span style="font-style:normal">, respectively</span></em><span style="layout-grid-mode:line">. A</span>ripiprazole<span style="layout-grid-mode: line"> dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of </span>aripiprazole<span style="layout-grid-mode: line"> with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Ketoconazole and other CYP3A4 inhibitors</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black;layout-grid-mode: line">In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and </span><span lang="EN-GB" style="color:black">C<span class="EMEASubscript">max</span><span style="layout-grid-mode:line"> by 63 % and 37 %, respectively. The AUC and </span>C<span class="EMEASubscript">max</span><span style="layout-grid-mode: line"> of dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with </span>aripiprazole<span style="layout-grid-mode:line">, potential benefits should </span>outweigh<span style="layout-grid-mode:line"> the potential risks to the patient. When concomitant administration of ketoconazole with </span>aripiprazole<span style="layout-grid-mode:line"> occurs, </span>aripiprazole<span style="layout-grid-mode:line"> dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2).</span> Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Carbamazepine and other CYP3A4 inducers</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of C<span class="EMEASubscript">max</span> and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when <span style="layout-grid-mode:line">aripiprazole (30 mg) was administered alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span class="EMEASubscript">max</span> and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine. Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of strong CYP3A4 inducers, the dosage of aripiprazole should be reduced to the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Valproate and lithium</span></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations </span><span lang="EN-GB">and therefore no dose adjustment is necessary when either valproate or lithium is administered with aripiprazole<span style="color:black">.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Potential for aripiprazole to affect other medicinal products</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The administration of ABILIFY solution for injection had no effect on the pharmacokinetics of lorazepam solution for injection when administered concomitantly. However, in a single-dose, intramuscular study of aripiprazole (dose 15 mg) in healthy subjects, administered simultaneously with intramuscular lorazepam (dose 2 mg), the orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical studies, oral doses of 10 mg/day to 30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism <i>in vitro</i>. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Serotonin syndrome</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.6     Fertility, pregnancy and lactation</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pregnancy</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborn infants should be monitored carefully (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Breast-feeding</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole/</span><span lang="EN-GB">metabolites are <span style="color:black">excreted in human milk. </span><em><span style="font-style:normal">A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from </span></em>aripiprazole<em><span style="font-style:normal"> therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal">Fertility</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB">Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.7     Effects on ability to drive and use machines</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-style:normal">Aripiprazole </span></em><span lang="EN-GB">has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1" style="page-break-after:auto"><span lang="EN-GB" style="color:black;text-transform:none">4.8     Undesirable effects</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Summary of the safety profile</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The most commonly reported adverse reactions in placebo-controlled trials were nausea, dizziness and somnolence each occurring in more than 3 % of patients treated with aripiprazole solution for injection.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Tabulated list of adverse reactions</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as "not known".</span></p><p class="EMEABodyText"><em><u><span lang="EN-GB" style="color:black;font-style: normal"><span style="text-decoration:none"> </span></span></u></em></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:-1.7pt;border-collapse:collapse;border:none" width="624"> <thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:92.15pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Common</span></b></p> </td> <td style="width:106.3pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Uncommon</span></b></p> </td> <td style="width:163.0pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Not known</span></b></p> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> </tr> </thead> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Blood and lymphatic system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Leukopenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Neutropenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Thrombocytopenia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Immune system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Allergic reaction (e.g. anaphylactic   reaction, angioedema including swollen tongue, tongue oedema, face oedema,   pruritus allergic, or urticaria)</span></em></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Endocrine disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperprolactinaemia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Diabetic hyperosmolar   coma</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Diabetic ketoacidosis</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Metabolism and nutrition disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-align:justify;text-autospace:none"><span lang="EN-GB" style="color:black">Diabetes mellitus</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Default"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Hyponatremia</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Anorexia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Psychiatric disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Insomnia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Anxiety</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Restlessness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Depression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypersexuality</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Suicide attempt, suicidal ideation and completed suicide   (see section 4.4)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pathological gambling</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Impulse-control   disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Binge eating</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Compulsive   shopping</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Poriomania</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aggression</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Agitation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nervousness </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Nervous system disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Akathisia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Extrapyramidal disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tremor</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Headache</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sedation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Somnolence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dizziness</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dystonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="IT" style="color:black">Restless legs syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Neuroleptic Malignant Syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="FR" style="color:black">Grand mal convulsion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Serotonin syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Speech disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Eye disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vision blurred</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diplopia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photophobia</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oculogyric crisis</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Cardiac disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tachycardia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sudden death unexplained </span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Torsades de pointes</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Ventricular arrhythmia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cardiac arrest</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Bradycardia</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Vascular disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Orthostatic hypotension</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Venous thromboembolism (including pulmonary embolism and   deep vein thrombosis)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypertension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Syncope</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Respiratory, thoracic and mediastinal disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hiccups</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Aspiration pneumonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Laryngospasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oropharyngeal spasm</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Gastrointestinal disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Constipation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dyspepsia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nausea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Salivary hypersecretion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vomiting</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Mouth dry</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pancreatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dysphagia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diarrhoea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Abdominal discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stomach discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Hepatobiliary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatic failure</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hepatitis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Jaundice</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rash</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Photosensitivity reaction</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alopecia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperhidrosis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Drug Reaction   with Eosinophilia and Systemic Symptoms (DRESS)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Musculoskeletal and connective tissue   disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rhabdomyolysis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Myalgia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Stiffness</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Renal and urinary disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary incontinence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Urinary retention</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Pregnancy, puerperium and perinatal conditions</span></b></em></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Drug withdrawal syndrome neonatal (see section 4.6)</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Reproductive system and breast disorders</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Priapism</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">General disorders and administration   site conditions</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Fatigue</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Temperature regulation disorder (e.g. hypothermia,   pyrexia)</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Chest pain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Peripheral oedema</span></p> </td> </tr> <tr> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p style="margin-bottom:0in;line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt;color:black">Investigations</span></b></p> </td> <td style="width:92.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diastolic blood pressure increased</span></p> </td> <td style="width:163.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="217"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Weight gain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alanine Aminotransferase </span><span lang="EN-GB" style="color:black">increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aspartate Aminotransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gamma-glutamyltransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alkaline phosphatase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">QT prolonged</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Glycosylated haemoglobin increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose fluctuation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Creatine phosphokinase increased</span></p> </td> </tr> </table><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Description of selected adverse reactions</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Extrapyramidal symptoms (EPS)</span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia: </span></i><span lang="EN-GB" style="color:black">in a long-term 52‑week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long-term 26‑week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26‑week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder: </span></i><span lang="EN-GB" style="color:black">in a 12‑week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients. In another 12‑week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long-term 26‑week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Akathisia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Dystonia</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Prolactin</span></em></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Laboratory parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see </span><span lang="EN-GB">section 4.4).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Reporting of suspected adverse reactions</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <span style="background:silver">via the national reporting system listed in <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V</a>.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">4.9     Overdose</span></b></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">No cases of overdose associated with adverse reactions were reported in clinical studies with ABILIFY solution for injection. Care must be taken to avoid inadvertent injection of this medicinal product into a blood vessel. Following any confirmed or suspected accidental overdose/inadvertent intravenous administration, close observation of the patient is needed and if any potentially medically serious sign or symptom develops, monitoring, which should include continuous electrocardiographic monitoring, is required. The medical supervision and monitoring should continue until the patient recovers.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Signs and symptoms</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed </span><span lang="EN-GB" style="color: black">included lethargy, increased blood pressure, somnolence, tachycardia, nausea, </span><span lang="EN-GB" style="color:black">vomiting and diarrhoea. </span><span lang="EN-GB" style="color:black">In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness </span><span lang="EN-GB" style="color:black">and extrapyramidal symptoms</span><span lang="EN-GB" style="color:black">.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Management of overdose</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole C<span class="EMEASubscript">max</span> by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in the treatment of overdose.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Haemodialysis</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">5.       PHARMACOLOGICAL PROPERTIES</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">5.1     Pharmacodynamic properties</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Mechanism of action</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D<sub>2</sub> and serotonin 5‑HT<sub>1A</sub> receptors and antagonism of serotonin 5‑HT<sub>2A</sub> receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in vitro</i> for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5‑HT<sub>1A</sub> and 5‑HT<sub>2A</sub> receptors and moderate affinity for dopamine D<sub>4</sub>, serotonin 5‑HT<sub>2C</sub> and 5‑HT<sub>7</sub>, alpha‑1 adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole doses ranging from 0.5 mg to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to the caudate and putamen detected by positron emission tomography.</span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Clinical efficacy and safety"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Clinical efficacy and safety</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Agitation in schizophrenia and Bipolar I Disorder with ABILIFY solution for injection</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two short- term (24-hour) placebo-controlled trials involving 554</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">schizophrenic adult patients presenting with agitation and disturbed behaviours, ABILIFYsolution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to haloperidol.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In one short-term (24-hour) placebo-controlled trial involving 291 patients with bipolar disorder presenting with agitation and disturbed behaviours, ABILIFY solution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to the reference arm lorazepam. </span><span lang="EN-GB" style="color:black">The observed mean improvement from baseline on the PANSS Excitement Component score at the primary 2-hour endpoint was 5.8 for placebo, 9.6 for lorazepam, and 8.7 for ABILIFY solution for injection. In subpopulation analyses on patients with mixed episodes or on patients with severe agitation, a similar pattern of efficacy to the overall population was observed but </span><span lang="EN-GB" style="color:black">statistical significance could not be established due to a reduced sample size.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Schizophrenia with oral aripiprazole</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In three short-term (4 to 6</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, oral aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52‑weeks was similar in both groups (oral aripiprazole 77 % and haloperidol 73 %). The overall completion rate was significantly higher for patients on oral aripiprazole (43 %) than for oral haloperidol (30 %). Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Åsberg Depression Rating Scale <a name="_Hlk8900809">(MADRS)</a> showed a significant improvement over haloperidol.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, oral aripiprazole had significantly greater reduction in relapse rate, 34 % in oral aripiprazole group and 57 % in placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Weight gain</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In clinical trials oral aripiprazole has not been shown to induce clinically relevant weight gain. In a 26‑week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on oral aripiprazole (n = 18, or 13 % of evaluable patients), compared to oral olanzapine (n = 45, or 33 % of evaluable patients).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Lipid parameters</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL).</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Prolactin</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></i></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Manic episodes in Bipolar I Disorder with oral aripiprazole</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two<b> </b>3‑week, flexible-dose, placebo-controlled monotherapy trials involving<b> </b>patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In one 3‑week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In two 12‑week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 6‑week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 26‑week, placebo-controlled trial, followed by a 74‑week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomisation, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">In a 52‑week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS] and MADRS with total scores ≤ 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores. In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilised for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The European Medicines Agency has deferred the obligation to submit the results of studies with </span><span lang="EN-GB" style="color:black">ABILIFY i</span><span lang="EN-GB" style="color:black">n one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">5.2     Pharmacokinetic properties</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Absorption</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole administered intramuscularly as a single-dose to healthy subjects is well absorbed and has an absolute bioavailability of 100 %. The aripiprazole AUC in the first 2</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">hours after an intramuscular injection was 90 % greater than the AUC after the same dose as a tablet; systemic exposure was generally similar between the 2</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">formulations. In 2</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">studies in healthy subjects the median times to the peak plasma concentrations were 1 and 3</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">hours after dosing.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Distribution"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Distribution</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><em><span lang="EN-GB" style="color:black;font-style:normal">Based on results from trials with oral administration of aripiprazole</span></em><span lang="EN-GB" style="color:black">, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 L/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Biotransformation</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in vitro</i> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40 % of aripiprazole AUC in plasma.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Elimination</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black"><span style="text-decoration:none"> </span></span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The total body clearance of aripiprazole is 0.7 mL/min/kg, which is primarily hepatic.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><u><span lang="EN-GB" style="color:black">Pharmacokinetics in special patient groups</span></u></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Elderly</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Gender</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB" style="color:black">Smoking</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB" style="color:black">Race</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Population pharmacokinetic evaluation showed no evidence of race‑related differences on the pharmacokinetics of aripiprazole.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Renal impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black">Hepatic impairment</span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">A single-dose study in subjects with varying degrees of liver cirrhosis (Child‑Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">5.3     Preclinical safety data</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Administration of ABILIFY solution for injection was well tolerated and produced no direct target organ toxicity in rats or monkeys after repeated dosing at systemic exposures (AUC) that were 15 and 5</span><span lang="EN-GB" style="color:black"> </span><span lang="EN-GB" style="color:black">times, respectively, human exposure at the maximum recommended human dose of 30 mg intramuscular. In intravenous reproductive toxicity studies, no new safety concerns were observed at maternal exposures up to 15 (rat) and 29 (rabbit) times human exposure at 30 mg.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Non-clinical data reveal no special hazard for humans based on conventional oral aripiprazole studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</span></p><p class="EMEABodyText"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m<span class="EMEASuperscript">2</span>). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39‑week study and are well below (6 %) their limits of <i>in vitro</i> solubility.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.1     List of excipients</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Sulfobutylether β-cyclodextrin (SBECD)</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Tartaric acid</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Sodium hydroxide</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Water for injections</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.2     Incompatibilities</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Not applicable.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.3     Shelf life</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">18 months</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">After opening: use product immediately.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.4     Special precautions for storage</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Keep the vial in the outer carton in order to protect from light.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">For storage conditions after first opening of the medicinal product, see section 6.3.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.5     Nature and contents of container</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Each carton contains one single-use type I glass vial with a rubber butyl stopper and a "tear-off" aluminium seal.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">6.6     Special precautions for disposal</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Otsuka Pharmaceutical Netherlands B.V.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Herikerbergweg 292</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">1101 CT, Amsterdam</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Netherlands</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">EU/1/04/276/036</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of first authorisation: 04 June 2004</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Date of latest renewal: 04 June 2009</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:black">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">{MM/YYYY}</span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black"> </span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">Detailed information on this medicinal product is available on the website of the European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>